Alexander Maxwell
Value, growth, long-term horizon, biotech

Kythera Pharmaceuticals: A Compelling Investment Opportunity With Potential Key Catalysts

Kythera Pharmaceuticals (NASDAQ:KYTH) is a very interesting pharmaceutical company. Kythera has been able to attract a large pharmaceutical partner to its main product and has the potential to substantially reward long-term oriented investors. Kythera has only one main drug in its development pipeline, however, if approved the drug has the potential to significantly boost revenue and lead to increased shareholder value.


ATX-101 is the only meaningful product currently under development in Kythera's pipeline. With that said, the product has many important upcoming catalysts which have the potential to drive significant shareholder growth. ATX-101 is being developed for the reduction of submental fat. ATX-101 if approved would be the first drug approved in this segment, which would allow...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details